| 2023 | | Impact of guideline adherence on the prognosis of Barcelona clinic liver cancer stage B hepatocellular carcinoma | 김순선, 노충균, 양민재, 이길호, 임선교, 정재연, 조효정, 한지은 |
| 2022 | | Incidence, mortality, and survival of liver cancer using Korea central cancer registry database: 1999–2019 | 김봉완, 김태규, 홍성연 |
| 2024 | | Incidentally found parotid gland lesion in 18F-FDG PET/CT for staging evaluation of patients with hepatocellular carcinoma: remote possibility of metastatic tumor or second primary salivary gland malignancy | 조효정 |
| 2004 | | Intra-arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein thrombosis | 김재근, 김진홍, 왕희정, 원제환, 이기명, 정재연, 조성원, 함기백 |
| 2020 | | Liver stiffness in magnetic resonance elastography is prognostic for sorafenib-treated advanced hepatocellular carcinoma | 김보현, 김순선, 김재근, 이제희, 정재연, 조효정, 허지미 |
| 2020 | | Liver stiffness measured by MR elastography is a predictor of early HCC recurrence after treatment | 김보현, 김순선, 김재근, 은정우, 이제희, 정재연, 조효정, 허지미 |
| 2008 | | Living donor liver transplantation for Patients with beyond Milan hepatocellular carcinoma | 김명욱, 김봉완, 배병구, 배재익, 왕희정, 원제환 |
| 2024 | | Multiomics profiling of buffy coat and plasma unveils etiology-specific signatures in hepatocellular carcinoma | 김순선, 은정우, 임수빈, 정재연, 조효정 |
| 1997 | | Natural History of Chronic Hepatitis Type B throughout Long-term Follow-up | - |
| 2022 | | Novel Gene Signatures as Prognostic Biomarkers for Predicting the Recurrence of Hepatocellular Carcinoma | 김순선, 은정우, 정재연, 조효정 |
| 2021 | | Overexpressed proteins in hcc cell-derived exosomes, CCT8, and cofilin-1 are potential biomarkers for patients with HCC | 김순선, 은정우, 정재연, 조효정 |
| 2023 | | Quantitative Prediction of Posttransplant Hepatocellular Carcinoma Prognosis Using ADV Score: Validation with Korea-Nationwide Transplantation Registry Database | 김봉완 |
| 1998 | | Relationship of Serum Anti-p53 Antibody with p53 Expression in Liver Tissue of Chronic Liver Diseases | - |
| 2021 | | Retrospective analysis of current guidelines for hepatocellular carcinoma diagnosis on gadoxetic acid–enhanced MRI in at-risk patients | 허지미 |
| 1998 | | Risk Factors and Treatment Strategy of Ruptured Hepatocellular Carcinoma | - |
| 2021 | | Role of immune cells in patients with hepatitis b virus‐related hepatocellular carcinoma | 정재연, 조효정 |
| 2010 | | Sarcomatoid hepatocellular carcinoma | 김영배, 석재연 |
| 2017 | | Second primary cancer after liver transplantation in hepatocellular carcinoma: a nationwide population-based study | 노오규, 오영택, 전미선, 허재성 |
| 2024 | | SGLT2i impact on HCC incidence in patients with fatty liver disease and diabetes: a nation-wide cohort study in South Korea | 김순선, 정재연, 조효정 |
| 2019 | | Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial | 정재연 |
| 2019 | | Staged partial hepatectomy versus transarterial chemoembolization for the treatment of spontaneous hepatocellular carcinoma rupture: a multicenter analysis in Korea | 김순선 |
| 2016 | | Surgical treatment for hepatocellular carcinoma with bile duct invasion | 김봉완, 왕희정, 홍성연 |
| 2019 | | The 7th/8th American Joint Committee on Cancer and the Modified Union for International Cancer Control Staging System for Hepatocellular Carcinoma | 김봉완, 왕희정, 홍성연 |
| 2021 | | Update on liver disease management during the pandemic of coronavirus disease 2019 (Covid-19): 2021 kasl guideline | 김순선 |
| 2021 | | Usefulness of cone-beam CT-based liver perfusion mapping for evaluating the response of hepatocellular carcinoma to conventional transarterial chemoembolization | 권요한 |
